Dorzolamide is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It is available as eye drops and ophthalmic solution. MedsAcross supplies Dorzolamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride ophthalmic solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Source: US FDA prescribing information
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP). Dorzolamide hydrochloride ophthalmic solution contains dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II.
Source: US FDA prescribing information
The dose is one drop of dorzolamide hydrochloride ophthalmic solution in the affected eye(s) three times daily. Dorzolamide hydrochloride ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
Source: US FDA prescribing information
Dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product.
Source: US FDA prescribing information
Sulfonamide Hypersensitivity () Bacterial Keratitis. Corneal Endothelium. Allergic Reactions. Acute Angle-Closure Glaucoma
Source: US FDA prescribing information
The most frequently reported adverse reactions associated with dorzolamide hydrochloride ophthalmic solution were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration. Superficial punctate keratitis occurred in 10 to 15% of patients and signs and symptoms of ocular allergic reaction in approximately 10%.
Source: US FDA prescribing information
Potential additive effect of oral carbonic anhydrase inhibitor with dorzolamide hydrochloride ophthalmic solution. () Potential acid-base and electrolyte disturbances.
Source: US FDA prescribing information
Storage Store dorzolamide hydrochloride ophthalmic solution, USP at 20°C to 25°C (68°F to 77°F). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Dorzolamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dorzolamide 20 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Dorzolamide 20 mg/mL ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 9 December 1994 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Dorzolamide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Dorzolamide and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Dorzolamide on 9 December 1994, according to Drugs@FDA.
No listed presentation of Dorzolamide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dorzolamide is classified under ATC code S01EC03 (Dorzolamide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.